Prevalence, Clinical Characteristics, and Prognostic Impact of Kidney Disease on Heart Failure Patients: An Observational Study of the Colombian Heart Failure Registry
Abstract Introduction: Chronic kidney disease (CKD) represents one of the most frequent comorbidities observed in heart failure (HF) patients and has been observed to increase this population’s risk of adverse outcomes. Nevertheless, evidence analyzing kidney dysfunction in HF is scarce in Latin Ame...
Saved in:
Published in | Cardiorenal medicine Vol. 13; no. 1; pp. 292 - 300 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Basel, Switzerland
01.01.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract
Introduction: Chronic kidney disease (CKD) represents one of the most frequent comorbidities observed in heart failure (HF) patients and has been observed to increase this population’s risk of adverse outcomes. Nevertheless, evidence analyzing kidney dysfunction in HF is scarce in Latin American populations. We aimed to analyze the prevalence of kidney dysfunction and assess its association with mortality in patients diagnosed with HF enrolled in the Colombian Heart Failure Registry (RECOLFACA). Methods: RECOLFACA enrolled adult patients with HF diagnosis from 60 centers in Colombia during the period 2017–2019. The primary outcome was all-cause mortality. A Cox proportional-hazards regression model was used to assess the impact of the different categories of eGFR in mortality risk. A p value of <0.05 was considered significant. All statistical tests were two-tailed. Results: From the total 2,514 evaluated patients, 1,501 (59.7%) patients had moderate kidney dysfunction (eGFR <60 mL/min/1.73 m2), while 221 (8.8%) patients were classified as having a severe kidney dysfunction (eGFR <30 mL/min/1.73 m2). Patients with lower kidney function were most commonly males, had higher median age, and reported a higher prevalence of cardiovascular comorbidities. Moreover, different patterns of medications prescription were observed when comparing CKD versus non-CKD patients. Finally, eGFR <30 mL/min/1.73 m2 was significantly associated with a higher mortality risk compared to eGFR >90 mL/min/1.73 m2 status (HR: 1.87; 95% CI, 1.10–3.18), even after an extensive adjustment by relevant covariates. Conclusion: CKD represents a prevalent condition in the setting of HF. Patients with CKD and HF present with multiple sociodemographic, clinical, and laboratory differences compared with those only diagnosed with HF and present a significantly higher risk of mortality. A timely diagnosis and optimal treatment and follow-up of CKD in the setting of HF may improve the prognosis of these patients and prevent adverse outcomes. |
---|---|
AbstractList | Introduction: Chronic kidney disease (CKD) represents one of the most frequent comorbidities observed in heart failure (HF) patients and has been observed to increase this population’s risk of adverse outcomes. Nevertheless, evidence analyzing kidney dysfunction in HF is scarce in Latin American populations. We aimed to analyze the prevalence of kidney dysfunction and assess its association with mortality in patients diagnosed with HF enrolled in the Colombian Heart Failure Registry (RECOLFACA). Methods: RECOLFACA enrolled adult patients with HF diagnosis from 60 centers in Colombia during the period 2017–2019. The primary outcome was all-cause mortality. A Cox proportional-hazards regression model was used to assess the impact of the different categories of eGFR in mortality risk. A p value of <0.05 was considered significant. All statistical tests were two-tailed. Results: From the total 2,514 evaluated patients, 1,501 (59.7%) patients had moderate kidney dysfunction (eGFR <60 mL/min/1.73 m2), while 221 (8.8%) patients were classified as having a severe kidney dysfunction (eGFR <30 mL/min/1.73 m2). Patients with lower kidney function were most commonly males, had higher median age, and reported a higher prevalence of cardiovascular comorbidities. Moreover, different patterns of medications prescription were observed when comparing CKD versus non-CKD patients. Finally, eGFR <30 mL/min/1.73 m2 was significantly associated with a higher mortality risk compared to eGFR >90 mL/min/1.73 m2 status (HR: 1.87; 95% CI, 1.10–3.18), even after an extensive adjustment by relevant covariates. Conclusion: CKD represents a prevalent condition in the setting of HF. Patients with CKD and HF present with multiple sociodemographic, clinical, and laboratory differences compared with those only diagnosed with HF and present a significantly higher risk of mortality. A timely diagnosis and optimal treatment and follow-up of CKD in the setting of HF may improve the prognosis of these patients and prevent adverse outcomes. Chronic kidney disease (CKD) represents one of the most frequent comorbidities observed in heart failure (HF) patients and has been observed to increase this population's risk of adverse outcomes. Nevertheless, evidence analyzing kidney dysfunction in HF is scarce in Latin American populations. We aimed to analyze the prevalence of kidney dysfunction and assess its association with mortality in patients diagnosed with HF enrolled in the Colombian Heart Failure Registry (RECOLFACA). RECOLFACA enrolled adult patients with HF diagnosis from 60 centers in Colombia during the period 2017-2019. The primary outcome was all-cause mortality. A Cox proportional-hazards regression model was used to assess the impact of the different categories of eGFR in mortality risk. A p value of <0.05 was considered significant. All statistical tests were two-tailed. From the total 2,514 evaluated patients, 1,501 (59.7%) patients had moderate kidney dysfunction (eGFR <60 mL/min/1.73 m2), while 221 (8.8%) patients were classified as having a severe kidney dysfunction (eGFR <30 mL/min/1.73 m2). Patients with lower kidney function were most commonly males, had higher median age, and reported a higher prevalence of cardiovascular comorbidities. Moreover, different patterns of medications prescription were observed when comparing CKD versus non-CKD patients. Finally, eGFR <30 mL/min/1.73 m2 was significantly associated with a higher mortality risk compared to eGFR >90 mL/min/1.73 m2 status (HR: 1.87; 95% CI, 1.10-3.18), even after an extensive adjustment by relevant covariates. CKD represents a prevalent condition in the setting of HF. Patients with CKD and HF present with multiple sociodemographic, clinical, and laboratory differences compared with those only diagnosed with HF and present a significantly higher risk of mortality. A timely diagnosis and optimal treatment and follow-up of CKD in the setting of HF may improve the prognosis of these patients and prevent adverse outcomes. INTRODUCTIONChronic kidney disease (CKD) represents one of the most frequent comorbidities observed in heart failure (HF) patients and has been observed to increase this population's risk of adverse outcomes. Nevertheless, evidence analyzing kidney dysfunction in HF is scarce in Latin American populations. We aimed to analyze the prevalence of kidney dysfunction and assess its association with mortality in patients diagnosed with HF enrolled in the Colombian Heart Failure Registry (RECOLFACA).METHODSRECOLFACA enrolled adult patients with HF diagnosis from 60 centers in Colombia during the period 2017-2019. The primary outcome was all-cause mortality. A Cox proportional-hazards regression model was used to assess the impact of the different categories of eGFR in mortality risk. A p value of <0.05 was considered significant. All statistical tests were two-tailed.RESULTSFrom the total 2,514 evaluated patients, 1,501 (59.7%) patients had moderate kidney dysfunction (eGFR <60 mL/min/1.73 m2), while 221 (8.8%) patients were classified as having a severe kidney dysfunction (eGFR <30 mL/min/1.73 m2). Patients with lower kidney function were most commonly males, had higher median age, and reported a higher prevalence of cardiovascular comorbidities. Moreover, different patterns of medications prescription were observed when comparing CKD versus non-CKD patients. Finally, eGFR <30 mL/min/1.73 m2 was significantly associated with a higher mortality risk compared to eGFR >90 mL/min/1.73 m2 status (HR: 1.87; 95% CI, 1.10-3.18), even after an extensive adjustment by relevant covariates.CONCLUSIONCKD represents a prevalent condition in the setting of HF. Patients with CKD and HF present with multiple sociodemographic, clinical, and laboratory differences compared with those only diagnosed with HF and present a significantly higher risk of mortality. A timely diagnosis and optimal treatment and follow-up of CKD in the setting of HF may improve the prognosis of these patients and prevent adverse outcomes. Abstract Introduction: Chronic kidney disease (CKD) represents one of the most frequent comorbidities observed in heart failure (HF) patients and has been observed to increase this population’s risk of adverse outcomes. Nevertheless, evidence analyzing kidney dysfunction in HF is scarce in Latin American populations. We aimed to analyze the prevalence of kidney dysfunction and assess its association with mortality in patients diagnosed with HF enrolled in the Colombian Heart Failure Registry (RECOLFACA). Methods: RECOLFACA enrolled adult patients with HF diagnosis from 60 centers in Colombia during the period 2017–2019. The primary outcome was all-cause mortality. A Cox proportional-hazards regression model was used to assess the impact of the different categories of eGFR in mortality risk. A p value of <0.05 was considered significant. All statistical tests were two-tailed. Results: From the total 2,514 evaluated patients, 1,501 (59.7%) patients had moderate kidney dysfunction (eGFR <60 mL/min/1.73 m2), while 221 (8.8%) patients were classified as having a severe kidney dysfunction (eGFR <30 mL/min/1.73 m2). Patients with lower kidney function were most commonly males, had higher median age, and reported a higher prevalence of cardiovascular comorbidities. Moreover, different patterns of medications prescription were observed when comparing CKD versus non-CKD patients. Finally, eGFR <30 mL/min/1.73 m2 was significantly associated with a higher mortality risk compared to eGFR >90 mL/min/1.73 m2 status (HR: 1.87; 95% CI, 1.10–3.18), even after an extensive adjustment by relevant covariates. Conclusion: CKD represents a prevalent condition in the setting of HF. Patients with CKD and HF present with multiple sociodemographic, clinical, and laboratory differences compared with those only diagnosed with HF and present a significantly higher risk of mortality. A timely diagnosis and optimal treatment and follow-up of CKD in the setting of HF may improve the prognosis of these patients and prevent adverse outcomes. |
Author | Echeverría, Luis Eduardo Rodríguez-Cerón, Álvaro Hernán López-Ponce de León, Juan David Rolong, Balkis García, Juan Camilo Manzur-Jatin, Fernando Rivera-Toquica, Fernando Posada-Bastidas, Alejandro Rivera-Toquica, Alex Ochoa-Morón, Alejandro David Saldarriaga, Clara Gómez-Mesa, Juan Esteban Pacheco-Jiménez, Oscar Alfredo Rodríguez-Gómez, Patricia Mosquera-Jiménez, José Ignacio |
Author_xml | – sequence: 1 givenname: Juan David surname: López-Ponce de León fullname: López-Ponce de León, Juan David – sequence: 2 givenname: Juan Esteban surname: Gómez-Mesa fullname: Gómez-Mesa, Juan Esteban email: *Juan Esteban Gómez-Mesa, juan.gomez.me@fvl.org.co – sequence: 3 givenname: Clara surname: Saldarriaga fullname: Saldarriaga, Clara – sequence: 4 givenname: Luis Eduardo surname: Echeverría fullname: Echeverría, Luis Eduardo – sequence: 5 givenname: Alejandro surname: Posada-Bastidas fullname: Posada-Bastidas, Alejandro – sequence: 6 givenname: Juan Camilo surname: García fullname: García, Juan Camilo – sequence: 7 givenname: Alejandro David orcidid: 0000-0002-6066-1367 surname: Ochoa-Morón fullname: Ochoa-Morón, Alejandro David – sequence: 8 givenname: Balkis surname: Rolong fullname: Rolong, Balkis – sequence: 9 givenname: Fernando surname: Manzur-Jatin fullname: Manzur-Jatin, Fernando – sequence: 10 givenname: José Ignacio surname: Mosquera-Jiménez fullname: Mosquera-Jiménez, José Ignacio – sequence: 11 givenname: Oscar Alfredo surname: Pacheco-Jiménez fullname: Pacheco-Jiménez, Oscar Alfredo – sequence: 12 givenname: Álvaro Hernán surname: Rodríguez-Cerón fullname: Rodríguez-Cerón, Álvaro Hernán – sequence: 13 givenname: Patricia surname: Rodríguez-Gómez fullname: Rodríguez-Gómez, Patricia – sequence: 14 givenname: Fernando orcidid: 0000-0003-3453-9605 surname: Rivera-Toquica fullname: Rivera-Toquica, Fernando – sequence: 15 givenname: Alex surname: Rivera-Toquica fullname: Rivera-Toquica, Alex |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37231884$$D View this record in MEDLINE/PubMed |
BookMark | eNptkU1P20AQhlcVVfkoh96raiUuICXtfsT2mltkSEGlIqJwtsbrcdhi74bdNVJ-EX8TR0lzqDjNaOaZd0bzHpI96ywS8oWz75wn-Q_GWCKZSsQHcsDTdDJOEib2trlUQu2T4xD-sjWX8pwln8i-zITkSk0OyOvc4wu0aDWOaNEaazS0tHgEDzqiNyEaHUYUbE3n3i2sWxfodbcc2tQ19JepLa7ohQkIAamz9ArBRzoD0_Ye6RyiQRvDOZ1aelsF9C9DxdlhyZ_Y16u1RnxEWrjWdZWB_-fvcDHc4FefyccG2oDH23hEHmaX98XV-Ob253UxvRlrmeZxXGmeaZ7KqhZKZ1wjV3mi5YQxEGmiQWnFdMUEZFklFJMyq1Fj1fAaUonA5RE53eguvXvuMcSyM0Fj24JF14dSKMGYyIe3DujZBtXeheCxKZfedOBXJWfl2ppyZ83AftvK9lWH9Y78Z8QAfN0AT-AX6HfAbv7k3XZx93tDlMu6kW8IyaFd |
CitedBy_id | crossref_primary_10_1007_s00392_024_02453_y |
Cites_doi | 10.4330/wjc.v7.i9.544 10.1016/j.cardfail.2007.03.011 10.1002/ejhf.821 10.1016/j.rec.2019.05.007 10.1016/s0195-668x(02)00700-5 10.1038/nrneph.2016.113 10.1161/CIRCULATIONAHA.105.580506 10.1097/MNH.0000000000000099 10.1161/CIRCOUTCOMES.113.000221 10.1093/eurheartj/eht386 10.1093/eurheartj/ehs205 10.1161/CIR.0000000000001063 10.1016/j.cardfail.2004.03.003 10.1155/2020/7692376 10.1056/NEJMoa041031 10.1016/j.medcli.2013.06.011 10.1007/s40620-020-00842-w 10.1093/eurheartj/ehr238 10.2174/1573403X14666180711124825 10.1136/openhrt-2015-000324 10.1016/S0140-6736(10)60674-5 10.1161/CIR.0000000000000664 10.1016/j.pcad.2011.01.003 10.1016/j.hfc.2008.03.008 10.1016/j.amjcard.2010.08.046 |
ContentType | Journal Article |
Copyright | 2023 The Author(s). Published by S. Karger AG, Basel 2023 The Author(s). Published by S. Karger AG, Basel. |
Copyright_xml | – notice: 2023 The Author(s). Published by S. Karger AG, Basel – notice: 2023 The Author(s). Published by S. Karger AG, Basel. |
DBID | M-- CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1159/000530852 |
DatabaseName | Karger Open Access Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: M-- name: Karger Open Access url: https://www.karger.com/OpenAccess sourceTypes: Enrichment Source Publisher |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 1664-5502 |
EndPage | 300 |
ExternalDocumentID | 10_1159_000530852 37231884 530852 |
Genre | Journal Article Observational Study |
GeographicLocations | Colombia |
GeographicLocations_xml | – name: Colombia |
GroupedDBID | 0~B 3O. 4.4 53G 8UI AAKDD AAYIC ABDBF ABPAZ ACGFS ACPSR ADBBV AENEX AEYAO AHMBA ALDHI ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CYUIP DIK E0A EBS EX3 FB. GROUPED_DOAJ HZ~ IAO IHR INH IY7 KUZGX M-- N9A O1H O9- OK1 OVD RKO RPM TEORI UJ6 WOW 0~5 3V. 7RV 7X7 8AO 8FI 8FJ ABJNI ABUWG AFJJK AFKRA AZPMC BENPR BKEYQ BPHCQ BVXVI CAG CCPQU CGR COF CUY CVF ECM EIF EJD FYUFA HMCUK HYE ITC NAPCQ NPM PQQKQ PROAC UKHRP AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c369t-bc17c163bd28c71ce1895c3400a265ca8c80cb02a77b280337decebf1da63ea13 |
IEDL.DBID | M-- |
ISSN | 1664-3828 |
IngestDate | Tue Aug 27 04:26:45 EDT 2024 Thu Sep 26 15:15:20 EDT 2024 Wed Oct 09 10:29:52 EDT 2024 Thu Aug 29 12:04:17 EDT 2024 Sat Aug 31 21:00:33 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Heart failure Chronic kidney disease Registry Mortality |
Language | English |
License | This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. 2023 The Author(s). Published by S. Karger AG, Basel. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c369t-bc17c163bd28c71ce1895c3400a265ca8c80cb02a77b280337decebf1da63ea13 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
ORCID | 0000-0002-6066-1367 0000-0003-3453-9605 |
OpenAccessLink | https://karger.com/doi/10.1159/000530852 |
PMID | 37231884 |
PQID | 2820029828 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | karger_primary_530852 proquest_miscellaneous_2820029828 crossref_primary_10_1159_000530852 pubmed_primary_37231884 |
PublicationCentury | 2000 |
PublicationDate | 2023-01-01 |
PublicationDateYYYYMMDD | 2023-01-01 |
PublicationDate_xml | – month: 01 year: 2023 text: 2023-01-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Basel, Switzerland |
PublicationPlace_xml | – name: Basel, Switzerland – name: Switzerland |
PublicationTitle | Cardiorenal medicine |
PublicationTitleAlternate | Cardiorenal Med |
PublicationYear | 2023 |
References | Vallianou NG, Mitesh S, Gkogkou A, Geladari E. Chronic kidney disease and cardiovascular disease: is there any relationship. Curr Cardiol Rev. 2019 Feb1515563. Schefold JC, Filippatos G, Hasenfuss G, Anker SD, von Haehling S. Heart failure and kidney dysfunction: epidemiology, mechanisms and management. Nat Rev Nephrol. 2016 Oct121061023. Chronic Kidney Disease Prognosis ConsortiumMatsushita K, van der Velde M, Astor BC, Woodward M, Levey AS. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010 Jun3759731207381. Deferrari G, Cipriani A, La Porta E. Renal dysfunction in cardiovascular diseases and its consequences. J Nephrol. 2021 Feb34113753. Gómez-Mesa JE, Saldarriaga-Giraldo CI, Echeverría LE, Luna-Bonilla PGrupo Investigador RECOLFACA. Registro colombiano de falla cardiaca (RECOLFACA): resultados. Rev Colomb Cardiol. 2021;28(4):334–42. Metra M, Cotter G, Gheorghiade M, Dei Cas L, Voors AA. The role of the kidney in heart failure. Eur Heart J. 2012 Sep3317213542. Komajda M, Follath F, Swedberg K, Cleland J, Aguilar JC, Cohen-Solal A. The EuroHeart Failure Survey programme: a survey on the quality of care among patients with heart failure in Europe. Part 2–treatment. Eur Heart J. 2003 Mar24546474. Becher PM, Fluschnik N, Blankenberg S, Westermann D. Challenging aspects of treatment strategies in heart failure with preserved ejection fraction: “Why did recent clinical trials fail?”. World J Cardiol. 2015 Sep7954454. Palaka E, Grandy S, van Haalen H, McEwan P, Darlington O. The impact of CKD anaemia on patients: incidence, risk factors, and clinical outcomes–a systematic literature review. Int J Nephrol. 2020;2020:7692376. Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco ALM, De Jong PE. Kidney disease: Improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013 Jan 1311150. Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail. 2007 Aug13642230. Lupón J, Bayés-Genís A. Mortality and heart failure hospitalizations. The need for an exhaustive, official, and standardized registry. Rev Esp Cardiol. 2019 Dec721298890. Conde Martel A. Extrapolation of results from clinical trials to heart failure patients hospitalized in Internal Medicine. Med Clin. 2014 May142104637. Damman K, Voors AA, Navis G, van Veldhuisen DJ, Hillege HL. The cardiorenal syndrome in heart failure. Prog Cardiovasc Dis. 2011 Oct54214453. Smith DH, Thorp ML, Gurwitz JH, McManus DD, Goldberg RJ, Allen LA. Chronic kidney disease and outcomes in heart failure with preserved versus reduced ejection fraction: the Cardiovascular Research Network PRESERVE Study. Circ Cardiovasc Qual Outcomes. 2013 May6333342. Kao DP, Kreso E, Fonarow GC, Krantz MJ. Characteristics and outcomes among heart failure patients with anemia and renal insufficiency with and without blood transfusions (public discharge data from California 2000–2006). Am J Cardiol. 2011 Jan10716973. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of cardiology/American heart association joint committee on clinical practice guidelines. Circulation. 2022;145(18):e895–94. Löfman I, Szummer K, Hagerman I, Dahlström U, Lund LH, Jernberg T. Prevalence and prognostic impact of kidney disease on heart failure patients. Open Heart. 2016 Jan31e000324. Blair JEA, Pang PS, Schrier RW, Metra M, Traver B, Cook T. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J. 2011 Oct3220256372. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004 Sep351131296305. Tsuruya K, Eriguchi M. Cardiorenal syndrome in chronic kidney disease. Curr Opin Nephrol Hypertens. 2015 Mar24215462. Herzog CA, Muster HA, Li S, Collins AJ. Impact of congestive heart failure, chronic kidney disease, and anemia on survival in the Medicare population. J Card Fail. 2004 Dec10646772. Löfman I, Szummer K, Dahlström U, Jernberg T, Lund LH. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction. Eur J Heart Fail. 2017 Dec1912160614. Damman K, Valente MAE, Voors AA, O’Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014 Feb35745569. Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American heart association. Circulation. 2019 Apr13916e84078. Gómez-Mesa JE, Saldarriaga CI, Echeverría LE, Luna PRECOLFACA Research Group. Colombian heart failure registry (RECOLFACA): methodology and preliminary data. Rev Colomb Cardiol. 2021;28(3):217–30. Ahmed A, Campbell RC. Epidemiology of chronic kidney disease in heart failure. Heart Fail Clin. 2008 Oct4438799. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJV, Yusuf S. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006 Feb11356718. ref13 ref12 ref15 ref14 ref11 ref10 ref2 ref1 ref17 ref16 ref19 ref18 ref24 ref23 ref25 ref20 ref22 ref21 ref8 ref7 ref9 ref4 ref3 ref6 ref5 |
References_xml | – ident: ref11 doi: 10.4330/wjc.v7.i9.544 – ident: ref21 doi: 10.1016/j.cardfail.2007.03.011 – ident: ref14 doi: 10.1002/ejhf.821 – ident: ref1 doi: 10.1016/j.rec.2019.05.007 – ident: ref9 doi: 10.1016/s0195-668x(02)00700-5 – ident: ref19 doi: 10.1038/nrneph.2016.113 – ident: ref17 doi: 10.1161/CIRCULATIONAHA.105.580506 – ident: ref20 doi: 10.1097/MNH.0000000000000099 – ident: ref24 doi: 10.1161/CIRCOUTCOMES.113.000221 – ident: ref22 doi: 10.1093/eurheartj/eht386 – ident: ref6 doi: 10.1093/eurheartj/ehs205 – ident: ref12 doi: 10.1161/CIR.0000000000001063 – ident: ref7 doi: 10.1016/j.cardfail.2004.03.003 – ident: ref25 doi: 10.1155/2020/7692376 – ident: ref18 doi: 10.1056/NEJMoa041031 – ident: ref10 doi: 10.1016/j.medcli.2013.06.011 – ident: ref16 doi: 10.1007/s40620-020-00842-w – ident: ref15 doi: 10.1093/eurheartj/ehr238 – ident: ref3 doi: 10.2174/1573403X14666180711124825 – ident: ref13 doi: 10.1136/openhrt-2015-000324 – ident: ref23 doi: 10.1016/S0140-6736(10)60674-5 – ident: ref4 doi: 10.1161/CIR.0000000000000664 – ident: ref5 doi: 10.1016/j.pcad.2011.01.003 – ident: ref2 doi: 10.1016/j.hfc.2008.03.008 – ident: ref8 doi: 10.1016/j.amjcard.2010.08.046 |
SSID | ssj0000561905 |
Score | 2.2967148 |
Snippet | Abstract
Introduction: Chronic kidney disease (CKD) represents one of the most frequent comorbidities observed in heart failure (HF) patients and has been... Chronic kidney disease (CKD) represents one of the most frequent comorbidities observed in heart failure (HF) patients and has been observed to increase this... Introduction: Chronic kidney disease (CKD) represents one of the most frequent comorbidities observed in heart failure (HF) patients and has been observed to... INTRODUCTIONChronic kidney disease (CKD) represents one of the most frequent comorbidities observed in heart failure (HF) patients and has been observed to... |
SourceID | proquest crossref pubmed karger |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 292 |
SubjectTerms | Adult Colombia - epidemiology Heart Failure - complications Heart Failure - diagnosis Heart Failure - epidemiology Humans Male Prevalence Prognosis Renal Insufficiency, Chronic - complications Renal Insufficiency, Chronic - epidemiology Research Article |
Title | Prevalence, Clinical Characteristics, and Prognostic Impact of Kidney Disease on Heart Failure Patients: An Observational Study of the Colombian Heart Failure Registry |
URI | https://karger.com/doi/10.1159/000530852 https://www.ncbi.nlm.nih.gov/pubmed/37231884 https://search.proquest.com/docview/2820029828 |
Volume | 13 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1LS8QwEA6iIl5EcdX1xSgeDWybtEm9yeqyKqsiCt5KXpVFbZd9HPxF_k3z6BZW2GvSJNCZJN9MZr5B6EIzyrWhEkdca0xNR2JrRhDME5YJIiXNtPN3DB7T_hu9f0_ea3-Hy4X5dPHPnhq14RawF64vPUcsOrCH7VrM0tQFbw0wbrwpDgdnPl4xSlOKibUjahqhhdGbaIMwi2g4pwv30HpYdjnK9LdNbxtt1TARroNcd9CKKXfRr-NbEj5L6BJqQs8v6C5SLl-CKDU8jysXQWcb4M7nQUJVwMNQl-YHbsKbDFQl9K2eT6Enhi44HZ4Dx-rkCq5LeJKNv9Yu4sINf9wcFi9C1x6Y346r_N_4F_Pha8e10Fvv9rXbx3WhBaxImk2xVBFTFphJHXPFImUiniWK2O0t4jRRgiveUbITC8akq2ZFmDbKyCLSIiVGRGQPrZZVaQ4QiKJgIhE-R4oSmvEAIqhkKosTKdrofP7b81Hg08i9HZJkeSOmNmoFgTSfzNuP_7V3XwahKx_poo3O5uLL7SZxLx-iNNVsklu70nPNx7yN9oNcmynmCnG4ZNEjtOlKzAe3yzFanY5n5sQCkak89Qb8qdfEPxT915k |
link.rule.ids | 315,786,790,870,27668,27957,27958 |
linkProvider | Karger AG |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prevalence%2C+Clinical+Characteristics%2C+and+Prognostic+Impact+of+Kidney+Disease+on+Heart+Failure+Patients%3A+An+Observational+Study+of+the+Colombian+Heart+Failure+Registry&rft.jtitle=Cardiorenal+medicine&rft.au=L%C3%B3pez-Ponce+de+Le%C3%B3n%2C+Juan+David&rft.au=G%C3%B3mez-Mesa%2C+Juan+Esteban&rft.au=Saldarriaga%2C+Clara&rft.au=Echeverr%C3%ADa%2C+Luis+Eduardo&rft.date=2023-01-01&rft.eissn=1664-5502&rft.volume=13&rft.issue=1&rft.spage=292&rft.epage=300&rft_id=info:doi/10.1159%2F000530852&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3828&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3828&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3828&client=summon |